Výsledky vyhledávání - Hawthorne, Thomas
- Zobrazuji výsledky 1 - 14 z 14
-
1
Chemical inhibition of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) by GSK2830371 potentiates the sensitivity to MDM2 inhibitors in a p53-dependent manner Autor Esfandiari, Arman, Hawthorne, Thomas A., Nakjang, Sirintra, Lunec, John
Vydáno 2016Text -
2
Initial Testing (Stage 1) of Glembatumumab Vedotin (CDX-011) by the Pediatric Preclinical Testing Program Autor Kolb, E. Anders, Gorlick, Richard, Billups, Catherine A., Hawthorne, Thomas, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Vydáno 2014Text -
3
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma Autor McGregor, Bradley A., Gordon, Michael, Flippot, Ronan, Agarwal, Neeraj, George, Saby, Quinn, David I., Rogalski, Mark, Hawthorne, Thomas, Keler, Tibor, Choueiri, Toni K.
Vydáno 2020Text -
4
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Autor Duvvuri, Umamaheswar, George, Jonathan, Kim, Seungwon, Alvarado, Diego, Neumeister, Veronique, Chenna, Ahmed, Gedrich, Richard, Hawthorne, Thomas, LaVallee, Theresa, Grandis, Jennifer R., Bauman, Julie E.
Vydáno 2019Text -
5
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies Autor Ansell, Stephen M., Flinn, Ian, Taylor, Matthew H., Sikic, Branimir I., Brody, Joshua, Nemunaitis, John, Feldman, Andrew, Hawthorne, Thomas R., Rawls, Tracey, Keler, Tibor, Yellin, Michael J.
Vydáno 2020Text -
6
MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB Autor Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.
Vydáno 2016Text -
7
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent Autor Marquez-Nostra, Bernadette V., Lee, Supum, Laforest, Richard, Vitale, Laura, Nie, Xingyu, Hyrc, Krzysztof, Keler, Tibor, Hawthorne, Thomas, Hoog, Jeremy, Li, Shunqiang, Dehdashti, Farrokh, Ma, Cynthia X., Lapi, Suzanne E.
Vydáno 2017Text -
8
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma Autor Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick
Vydáno 2014Text -
9
IT-30 ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA Autor Reardon, David, Schuster, James, Tran, David, Fink, Karen, Nabors, Louis, Li, Gordon, Lukas, Rimas, Desjardins, Annick, Ashby, Lynn, Duic, J. Paul, Aneiro, Lynn, Hawthorne, Thomas, Green, Jennifer, Yellin, Michael, Davis, Thomas, Sampson, John
Vydáno 2014Text -
10
Phase 2 Trial of the GPNMB-Targeted Antibody-Drug Conjugate, Glembatumumab Vedotin (CDX-011) in Recurrent Osteosarcoma AOST1521: A Report from the Children’s Oncology Group (COG) Autor Kopp, Lisa M., Malempati, Suman, Krailo, Mark, Gao, Yun, Buxton, Allen, Weigel, Brenda J., Hawthorne, Thomas, Crowley, Elizabeth, Moscow, Jeffrey A., Reid, Joel M., Villalobos, Victor, Randall, R. Lor, Gorlick, Richard, Janeway, Katherine A.
Vydáno 2019Text -
11
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers Autor Anandasabapathy, Niroshana, Breton, Gaëlle, Hurley, Arlene, Caskey, Marina, Trumpfheller, Christine, Sarma, Popi, Pring, James, Pack, Maggi, Buckley, Noreen, Matei, Irina, Lyden, David, Green, Jennifer, Hawthorne, Thomas, Marsh, Henry C., Yellin, Michael, Davis, Thomas, Keler, Tibor, Schlesinger, Sarah J.
Vydáno 2015Text -
12
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study Autor Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Vydáno 2021Text -
13
3BNC117 a Broadly Neutralizing Antibody Suppresses Viremia in HIV-1-Infected Humans Autor Caskey, Marina, Klein, Florian, Lorenzi, Julio C. C., Seaman, Michael S., West, Anthony P., Buckley, Noreen, Kremer, Gisela, Nogueira, Lilian, Braunschweig, Malte, Scheid, Johannes F., Horwitz, Joshua A., Shimeliovich, Irina, Ben Avraham-Shulman, Sivan, Witmer-Pack, Maggi, Platten, Martin, Lehmann, Clara, Burke, Leah A., Hawthorne, Thomas, Gorelick, Robert J., Walker, Bruce D., Keler, Tibor, Gulick, Roy M., Fätkenheuer, Gerd, Schlesinger, Sarah J., Nussenzweig, Michel C.
Vydáno 2015Text -
14
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption Autor Scheid, Johannes F., Horwitz, Joshua A., Bar-On, Yotam, Kreider, Edward F., Lu, Ching-Lan, Lorenzi, Julio C. C., Feldmann, Anna, Braunschweig, Malte, Nogueira, Lilian, Oliveira, Thiago, Shimeliovich, Irina, Patel, Roshni, Burke, Leah, Cohen, Yehuda Z., Hadrigan, Sonya, Settler, Allison, Witmer-Pack, Maggi, West, Anthony P., Juelg, Boris, Keler, Tibor, Hawthorne, Thomas, Zingman, Barry, Gulick, Roy M., Pfeifer, Nico, Learn, Gerald H., Seaman, Michael S., Bjorkman, Pamela J., Klein, Florian, Schlesinger, Sarah J., Walker, Bruce D., Hahn, Beatrice H., Nussenzweig, Michel C., Caskey, Marina
Vydáno 2016Text